Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs
14. Februar 2022 14:05 ET
|
Biofrontera AG
Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the “Company”) (Nasdaq: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, decided today its...
Biofrontera AG announces mediation results
19. November 2021 08:45 ET
|
Biofrontera AG
Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (ISIN: DE0006046113) has been in mediation proceedings with Mr. Wilhelm K. T....
Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021
17. November 2021 17:00 ET
|
Biofrontera AG
Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021
09. November 2021 05:45 ET
|
Biofrontera AG
Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Biofrontera AG receives FDA-approval of the BF-RhodoLED® XL lamp
22. Oktober 2021 09:55 ET
|
Biofrontera AG
Leverkusen, Germany, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced the...
Biofrontera reports preliminary revenue for the month of August 2021
08. September 2021 12:10 ET
|
Biofrontera AG
Leverkusen, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Biofrontera reports financial results for the six months ended June 30, 2021
19. August 2021 11:47 ET
|
Biofrontera AG
Leverkusen, Germany, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021
12. August 2021 08:55 ET
|
Biofrontera AG
Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Biofrontera reports preliminary revenue for the month of July 2021
09. August 2021 09:00 ET
|
Biofrontera AG
Leverkusen, Germany, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland
23. Juli 2021 04:15 ET
|
Biofrontera AG
Leverkusen, Germany, July 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Medac Gesellschaft für...